Navigation Links
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
Date:10/8/2007

NEW YORK, Oct. 8 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 16, 2007. Later that day, at 10:00 AM EDT, Forest will host a conference call where Dr. Lawrence Olanoff, President and Chief Operating Officer and Frank Perier, Senior Vice President and Chief Financial Officer, will discuss the financial results and relevant company and industry topics. The conference call will be webcast live beginning at 10:00 AM EDT on the Company's website http://www.frx.com and also on the website http://www.streetevents.com. Please log on to either website at least fifteen minutes prior to the conference call as it may be necessary to download software to access the call. A replay of the conference call will be available until October 31, 2007 at both websites and also by dialing 1-800-642-1687 (US investors) or +1-706-645-9291 (international investors), ID 19769552.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a U.S.-based pharmaceutical company dedicated to identifying, developing, and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and for generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl-D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate and severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil- hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2007.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bird flu threat ruled out: Karnataka Forest Department
2. Will The Tropical Forests Survive The Deforestation Scenario?
3. Higher Health Cost Due to Forest Fires
4. Forest Fire Affects Singapores Air Quality
5. India to Protect Its Forests With the Aid of Austrian NGO
6. Human Induced Nitrogen Deposition Increasing Carbon Sequestration in Forests
7. Deforestation Plays a Critical Role in Climate Change: Study
8. China Unveils Green Plan to Revert Farmland to Forest
9. Northern Forests Less Effective Than Tropical Forests in Reducing Global Warming
10. International Conference On Malaria - Laveran To Genomics
11. African Conference to Combat AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... 2017 , ... Ecommerce sales have grown every year since the 1990’s, with ... The consequences of rapid innovation and growth are often neglected in the name of ... business and individual’s job to give something back to the planet that provides the ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is ... overcome their mental health struggles. The Alive team uses advanced behavioral sciences treatment ... in dealing with a mental health struggle is based on 10 modalities of ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
(Date:4/18/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company founded ... infections, will present preclinical data supporting the use of ... (MDR) Gram-negative infections at the 27th European Congress of ... in Vienna, Austria . ... "Our ongoing preclinical ...
Breaking Medicine Technology: